GlaxoSmithKline News and Research

RSS

Recombinant SARS-CoV-2 protein vaccine less immunogenic but more antigenic than expected

Now, a new preprint research paper posted to the medRxiv server presents preliminary results of a stabilized SARS-CoV-2 pre-fusion spike protein vaccine expressed in a baculovirus system (CoV2 preS dTM), with two different adjuvant formulations.

26 Jan 2021

Systemic lupus erythematosus disproportionately affects ethnic female population

Just over 200,000 Americans suffer from systemic lupus erythematosus, or SLE, a condition in which the body's immune system mistakenly attacks its own healthy tissues, especially joints and skin, a new study shows.

21 Jan 2021

COVID-19 has transformed the world of vaccines

Researchers at GlaxoSmithKline (GSK) in Italy and Belgium say the coronavirus disease 2019 (COVID-19) pandemic is transforming the world of vaccinology by accelerating vaccine development and the availability of powerful technologies.

20 Jan 2021

Study shows COVID-19 pneumonia is different from typical pneumonia

Bacteria or viruses like influenza that cause pneumonia can spread across large regions of the lung over the course of hours. In the modern intensive care unit, these bacteria or viruses are usually controlled either by antibiotics or by the body's immune system within the first few days of the illness.

12 Jan 2021

Many lighter smokers can be addicted to cigarettes

Even people who consider themselves to be casual cigarette smokers may be addicted, according to current diagnostic criteria.

23 Dec 2020

Antiepileptic drug reduces early signs of clinical dysfunction in people with ALS

The antiepileptic drug ezogabine reduced pathologic excitability of cortical and spinal motor neuron cells that are early signs of clinical dysfunction in people with amyotrophic lateral sclerosis (ALS), according to a study conducted by the Neurological Clinical Research Institute of Massachusetts General Hospital.

10 Dec 2020

How pharma money colors Operation Warp Speed’s quest to defeat COVID

April 16 was a big day for Moderna, a Massachusetts biotech company on the verge of becoming a front-runner in the U.S. government's race for a coronavirus vaccine. It had received roughly half a billion dollars in federal funding to develop a COVID shot that might be used on millions of Americans.

30 Nov 2020

Study examines financial penalties levied on large pharmaceutical companies for illegal activities

Some pharmaceutical companies have received criticism for engaging in illegal activities, such as providing kickbacks and bribes, knowingly shipping adulterated or contaminated drugs to pharmacies, and marketing drugs for unapproved uses.

18 Nov 2020

CEAT project for improving ovarian cancer diagnosis, treatment shows promise

Porvair Sciences reports, due to promising results, it has agreed with its collaborative partners to make additional investment in the CEAT project which aims to dramatically improve the diagnosis and treatment of ovarian cancer.

From Porvair Sciences Limited 16 Nov 2020

Stewart Kay joins Adaptate Biotherapeutics as Chief Business Officer

Adaptate Biotherapeutics, a company focused on developing antibody-based therapeutics for modulation of gamma delta T cells, today announced the appointment of Stewart Kay as Chief Business Officer.

28 Oct 2020

Scientists receive £265,000 to investigate link between vascular dementia and heart disease

Scientists from the University of Sheffield and University of Manchester have been awarded £265,000 from the British Heart Foundation, to investigate the links between vascular dementia and heart disease, and test whether a drug currently used to treat arthritis could also be used as a treatment for vascular dementia.

16 Oct 2020

Cincinnati Children's research leads to approval of new drug for hypereosinophilic syndrome

Following two decades of research on a group of rare diseases called hypereosinophilic syndrome at Cincinnati Children's Hospital Medical Center, the U.S. Food and Drug Administration has approved the drug Nucala (mepolizumab) for use in the treatment of patients with hypereosinophilic syndrome.

28 Sep 2020

FDA approves first drug for patients with hypereosinophilic syndrome in nearly 14 years

Today, the U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.

25 Sep 2020

These secret safety panels will pick the COVID vaccine winners

Most Americans have never heard of Dr. Richard Whitley, an expert in pediatric infectious diseases at the University of Alabama-Birmingham.

24 Sep 2020

Immunotherapy benefits patients with gastric and esophageal cancers, new data shows

New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and esophageal cancers who currently have poor survival.

21 Sep 2020

Common heart drugs are safe for patients hospitalized with COVID-19

Heart patients hospitalized with COVID-19 can safely continue taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), according to the BRACE CORONA trial presented in a Hot Line session today at ESC Congress 2020.

1 Sep 2020

Vitamin D supplements do not prevent severe asthma attacks in children

Contrary to earlier results, vitamin D supplements do not prevent severe asthma attacks in at-risk children, according to the first placebo-controlled clinical trial to test this relationship.

25 Aug 2020

Calcified plaque in the arteries better predicts future heart attacks than strokes

The amount of calcified plaque in the heart's arteries is a better predictor of future heart attacks than of strokes, with similar findings across sex and racial groups, according to new research from UT Southwestern.

18 Aug 2020

Combination therapy effective for patients with cholangiocarcinoma marked by BRAF mutations

In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, achieved a 51% overall response rate (ORR) in patients with cholangiocarcinoma marked by the BRAF V600E mutation.